Director/PDMR Shareholding

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.

Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy

To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.

Diaceutics PLC
Ryan Keeling, Chief Executive Officer	Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer	investorrelations@diaceutics.com

Canaccord Genuity Limited (Nomad & Broker)	Tel: +44 (0)20 7253 8000
Simon Bridges, Andrew Potts, Harry Rees

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Delia Keeling
2	Reason for notification
a.	Position/Status	PCA to Peter Keeling, Chair
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64
b.	Nature of the transaction	Sale
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£1.90	1,750,000

d.	Date of the transaction	12 November 2026
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Peter Keeling
2	Reason for notification
a.	Position/Status	Chair
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64
b.	Nature of the transaction	Sale
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£1.90	1,750,000

d.	Date of the transaction	12 November 2026
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Robyn Keeling
2	Reason for notification
a.	Position/Status	PCA to Ryan Keeling, Chief Executive Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64
b.	Nature of the transaction	Sale
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£1.90	100,000

d.	Date of the transaction	12 November 2026
e.	Place of the transaction	AIM Market of the London Stock Exchange

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1	Details of the person discharging managerial responsibilities/person closely associated
a.	Name	Ryan Keeling
2	Reason for notification
a.	Position/Status	Chief Executive Officer
b.	Initial notification/ Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Diaceutics PLC
b.	LEI	213800VEWQBB39ZB8J81
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the financial instrument, type of instrument Identification Code	Ordinary shares of £0.002 each ISIN: GB00BJQTGV64
b.	Nature of the transaction	Sale
c.	Price(s) and volume(s)
			Price(s)	Volume(s)
			£1.90	500,000

d.	Date of the transaction	12 November 2026
e.	Place of the transaction	AIM Market of the London Stock Exchange

Summary by AI ^BETAClose X

Companies

UK 100

Latest directors dealings

NOTIFICATION OF MAJOR HOLDINGS
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii:			Diaceutics PLC ORD GBP0.002
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer
2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights						X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name			Peter Keeling
City and country of registered office (if applicable)			NA
4. Full name of shareholder(s) (if different from 3.) v
Name
City and country of registered office (if applicable)
5. Date on which the threshold was crossed or reached vi:			12 November 2026
6. Date on which issuer notified:			12 November 2026
7. Total positions of person(s) subject to the notification obligation
	% of voting rights attached to shares (total of 8. A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)		Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached	13.78%	0.33%		14.11%	12,034,517
Position of previous notification (if applicable)	17.88%	0.33%		18.21%	15,534,517

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
8 A: Voting rights attached to shares
Class/type of shares ISIN code (if possible)		Number of voting rights ix					% of voting rights
		Direct (DTR5.1)		Indirect (DTR5.2.1)			Direct (DTR5.1)		Indirect (DTR5.2.1)
Ordinary share of £0.002 (GB00BJQTGV64)		5,626,025		6,126,024			6.60%		7.18%


SUBTOTAL 8. A		11,752,049					13.78%

8 B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument		Expiration date x	Exercise/ Conversion Period xi			Number of voting rights that may be acquired if the instrument is exercised/converted.			% of voting rights



			SUBTOTAL 8. B 1

8 B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument	Expiration date x		Exercise/ Conversion Period xi		Physical or cash Settlement xii			Number of voting rights	% of voting rights
Employee share option	17/04/27		17/04/23 to 17/04/27		£1.265 per share			180,000	0.21%
Employee share option	18/05/30		18/05/26 to 18/05/30		£0.002 per share			102,468	0.12%

					SUBTOTAL 8.B.2			282,468	0.33%

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv				X
Name xv	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
Peter Keeling	6.60%	0.33%	6.93%
Delia Keeling	7.18%	-%	7.18%




10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held

11. Additional information xvi

Place of completion	AIM Market of the London Stock Exchange
Date of completion	13 November 2026

Director/PDMR Shareholding

Summary by AI BETAClose X

Companies

UK 100

Latest directors dealings

Summary by AI ^BETAClose X